Cormorant Asset Management, LP Beam Therapeutics Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $2.69 Million - $5.62 Million	-90,045 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $22 Million - $33.7 Million	-409,955 Reduced 81.99%	90,045 $5.16 Million
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $27.2 Million - $39.6 Million	400,000 Added 400.0%	500,000 $39.8 Million
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $4.6 Million - $9.24 Million	-71,775 Reduced 41.78%	100,000 $12.9 Million
Q1 2021 May 17, 2021	SELL	$71.28 - $120.75 $53.6 Million - $90.9 Million	-752,474 Reduced 81.41%	171,775 $13.7 Million
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $2.84 Million - $12.2 Million	127,821 Added 16.05%	924,249 $75.5 Million
Q3 2020 Nov 16, 2020	SELL	$19.0 - $30.57 $19 - $30	-1 Reduced -0.0%	796,428 $19.6 Million
Q1 2020 May 15, 2020	BUY	$13.31 - $29.2 $10.6 Million - $23.3 Million	796,429 New	796,429 $14.3 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.69B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.